<DOC>
	<DOC>NCT02025712</DOC>
	<brief_summary>The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.</brief_summary>
	<brief_title>Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus exemestane.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Postmenopausal women as defined in the protocol page 9; Histologically and/or cytologically confirmed invasive breast cancer with stage IV disease according to AJCC; Confirmed ER/PRpositive, and HER2 negative tumor; Disease progression on or following prior endocrine therapy with tamoxifen or nonsteroidal aromatase inhibitor, as defined in protocol, prior to standard of care (SOC) induction chemotherapy Patient with documented evidence of visceral disease (including but not limited to hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor assessments; ECOG performance status ≤ 2 or Karnofsky performance status ≥ 50% prior to the start of study treatment; Adequate organ function prior to the start of study treatment as defined in the protocol; Able to swallow and retain oral medication; Able to give written informed consent; Male patient; Metastatic disease limited to the bone or soft tissues only and with no history of other visceral metastases; History of brain or other CNS metastases; Previous treatment with exemestane, unless exemestane was administered in the adjuvant setting and stopped &gt;1 year before metastatic relapse; Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC or treated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC without clinical benefit; History of neurological or psychiatric disorders; Any serious cardiovascular diseases in the previous 6 months; Impairment of gastrointestinal function or gastrointestinal disease; Patients with uncontrolled infection; Patients with an active, bleeding diathesis or on oral antivitamin K medication (except low dose coumadin defined as 1 mg a day); Chronic treatment with systemic steroids or another immunosuppressive agent; Patients with a preexisting peripheral neuropathy &gt; grade 1; Patients who are hepatitis B and/or hepatitis C carriers; Known human immunodeficiency virus infection; Prior exposure to mTOR inhibitors; Hypersensitivity to rapamycin or other similar compounds; Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP will not be included in this study; Prior treatment with any investigational agent within the preceding 4 weeks; Other conditions in the judgment of the investigator, would make the patient inappropriate for entry into this study. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>